Section Arrow
Quote
JAZZ.NASDAQ
- Jazz Pharmaceuticals plc
Quotes are at least 15-min delayed:2026/10/18 19:15 EDT
Regular Hours
Last
 210.23
-4.19 (-1.95%)
Day High 
214.775 
Prev. Close
214.42 
1-M High
247.31 
Volume 
636.71K 
Bid
200
Ask
213
Day Low
208.15 
Open
214.25 
1-M Low
209.34 
Market Cap 
13.92B 
Currency 美元 
P/E 14.68 
%Yield -- 
10-SMA 222.64 
20-SMA 229.67 
50-SMA 240.86 
52-W High 266.375 
52-W Low 128.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
14.61/20.78
Enterprise Value
18.30B
Balance Sheet
Book Value Per Share
73.97
Cash Flow
Cash Flow Yield
0.12
Income Statement
Total Revenue
4.27B
Operating Revenue Per Share
58.45
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.